Novonesis A/S Earnings Call Signals Confident Growth

Novonesis A/S – Adr ((NVZMY)) has held its Q1 earnings call. Read on for the main highlights of the call.

Novonesis A/S opened 2026 with a broadly upbeat earnings call, underscoring solid organic growth, resilient margins and strong cash generation despite notable currency and cost headwinds. Management emphasized that synergies from recent deals, healthy demand across key end markets and disciplined execution support confidence in both the full‑year outlook and long‑term growth ambitions.

Solid Group Growth Powered by Volume and M&A

Group organic sales rose 7% in Q1 2026, with reported revenue up 4% as volume remained the main engine of growth. Sales synergies and pricing each added about 1 percentage point, while recent acquisitions contributed another 3 points, allowing Novonesis to reaffirm its 5%–7% organic growth outlook for 2026 despite exiting selected markets.

Food & Beverages Delivers Double‑Digit Expansion

The Food & Beverages division stood out with 11% organic growth, supported by broad geographic penetration and strength across dairy categories. Pricing added roughly 1 percentage point, while both dairy and fresh dairy solutions saw robust demand, reinforcing Novonesis’ positioning with food manufacturers seeking efficiency and healthier formulations.

Food & Health and Planetary Health Maintain Momentum

Food & Health achieved 9% organic growth, while Planetary Health advanced 5%, helped by inventory buildup at a major animal nutrition customer. The company launched five new biosolutions, including an advanced yogurt culture, a Bovacillus probiotic promising up to 1 kilogram more milk per cow per day, and the ActiPhy enzyme aimed at lifting corn yields by about 3%.

Margins Stay Strong Despite Investment Phase

Adjusted gross margin improved by 120 basis points to 60.1%, reflecting a richer product mix and operational efficiency gains. The adjusted EBITDA margin held at a high 37.8% versus 38.3% a year earlier, and management still expects full‑year margins between 37% and 38% with expansion versus 2025.

Earnings Growth, Cash Strength and Financing Achievements

Adjusted EPS rose 8% year on year to €0.57, driven by higher profitability and disciplined cost control. Operating cash flow climbed to €167.1 million and free cash flow before acquisitions increased 9% to €74 million, while the company also successfully placed €1.7 billion of senior unsecured notes and strengthened its credit profile.

Integration Synergies and Global Capacity Build‑Out

The Feed Enzyme Alliance acquisition, completed roughly ten months ago, is tracking as planned and contributed around 50 basis points to EBITDA through synergies. Novonesis also bought a production facility in Thailand, targeted to be operational in 2027, and has embedded further capacity investments into its CapEx plan through 2030 to support future growth and HMO scale‑up.

Structural Growth Drivers Support Long‑Term Ambition

Management highlighted structural demand for biosolutions that boost yields, support healthier nutrition and enable bioenergy, underpinned by strong customer dialogues. Interest is particularly robust in Southeast Asia and India, giving the company confidence to reiterate its 2030 organic CAGR target of 6%–9% and its leadership in key biosolutions niches.

Currency Headwinds Weigh on Reported Results

Foreign exchange movements were a notable drag, reducing reported sales by about 6 percentage points in the quarter. Management also expects roughly a 0.5 percentage‑point FX headwind on the full‑year EBITDA margin, partially masking the underlying operational improvement visible in organic and margin metrics.

Operating Expense Step‑Up Pressures Margins Near Term

Total operating expenses, excluding purchase‑price‑allocation amortization, rose to 29.1% of sales from 27.3% a year ago as Novonesis invested in additional commercial resources. This deliberate spend contributed to a modest 50 basis‑point year‑on‑year dip in adjusted EBITDA margin to 37.8%, framed by management as necessary to capture future growth.

Higher Input Costs and CapEx Temporarily Lift Cash Outlays

Management signaled a temporary increase in capital expenditure, with 2026 CapEx expected at 12%–14% of sales versus 8.3% in Q1. The higher spend will fund capacity expansion, including projects to double U.S. dairy culture capacity and ramp the new Thailand site, resulting in elevated near‑term cash needs but supporting longer‑term scalability.

Soft Patch in North American Probiotics

Human Health posted 5% organic growth, but dietary supplements and probiotics in North America were softer due to weaker consumer demand. Management pointed to declining online search activity and volume pressure in that region, describing the trend as a short‑term headwind rather than a structural reset of the probiotics opportunity.

Tech and Plant Volatility Driven by Order Timing

Within Agriculture, Energy & Tech, overall growth was 5%, but the tech subsegment saw a double‑digit decline due to order timing and challenging comparisons. The small plant business also declined and was characterized as lumpy and timing‑driven, with management stressing that neither area reflects a structural loss of business.

Sales Mix and FX Dilute Divisional Margins

Despite the stronger group gross margin, divisional profitability in Food & Health came under some pressure from product mix and currency impacts. The EBITDA margin for that segment declined by 130 basis points year on year to 35.7%, as faster‑growing categories such as HMOs and FX effects weighed on the reported margin profile.

Guidance and Outlook: Confident Growth with Investment

Novonesis reiterated full‑year guidance, calling for 5%–7% organic sales growth driven mainly by volume, with around 1 percentage point each from pricing and sales synergies and an extra lift from deferred revenue in Human Health. The company targets a 37%–38% adjusted EBITDA margin, CapEx of 12%–14% of sales and year‑end leverage near 1.7 times, while absorbing FX and cost headwinds and banking further benefits from the Feed Enzyme Alliance.

Looking ahead, Novonesis’ earnings call painted a picture of a company balancing strong underlying growth and profitability with a deliberate step‑up in investment. For investors, the key takeaways are resilient demand, expanding capacity and disciplined capital allocation, with management signaling that short‑term FX and cost pressures are manageable against a compelling long‑term biosolutions growth story.